July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene.
…
- thasso
- about
- thasso social
- thasso service
- theragenomics: useful links
- theragenomics: survey at thasso
- theragenomics: biomarkers
- theragenomics: companion tests
- theragenomics: drug labels with annotated information
- theragenomics: targeted therapies
- theragenomics: drugs and genes
- theragenomics: allele-related guideline information
- theragenomics: videos
- drugs: interactions
- drugs: general information
- drugs: adverse reactions
- drugs: risk evaluation and mitigation strategies (REMS)
- drugs: patients voices
- thasso academy
- health authorities
- public domain
- Clinical Pharmacogenetics Implementation Consortium
- ACMG Genetic Test Fact Sheets
- Public Health Genomics Knowledge Base
- The Human Diagnosis Project
- Phenotypes And Genotypes Database
- Genetic Alliance UK
- Genetics Generation
- Front Line Genomics
- Alliance for Cancer Gene Therapy (ACGT)
- EUPATI The European Patients’ Academy on Therapeutic Innovation
- European Patient Forum
- Uppsala Monitoring Center
- World Health Organisation (WHO)
- von Hippel Lindau Syndrome (VHL)
- Cerebral Palsy Symptoms
- Mesothelioma Fund
- Multiple Myeloma Research Foundation
- Open Source Pharma (OSP, Medicine for All)
- theragenomics worldwide
- patient & consumer health
- digital therapeutics in theragenomic medicine
- miscellaneous
- Partners Health Care / Personalized Medicine
- Worst Pills / Best Pills
- Pharmagenomics Research Network
- Mayo Clinic: Personalized Medicine
- Patient Power
- Patient Opinion (UK)
- Drug Injury Watch (Tom Lamb)
- Ways To Fund Cancer Treatments
- MedScape India
- Swiss Academy of Medical Sciences
- IDICAP: An Integrated Drug Intervention for Cancer Panel
- PanDrugs
- Soccer Genomics
- companies
- products
- thasso post
- $ donations
english
deutsch
français
thasso: recent comments